Aurobindo Pharma receives USFDA Approval for Ibandronate Sodium Injection
At the estimate market size of $422 million for 12 months, the generic version of Prilosec delayed-release capsules by Aurobindo Pharma will be launched in the US Aurobindo Pharma has received the green signal from the USFDA to market the generic version of Prilosec delayed-release capsule in the strengths of 10mg, 20mg, and 40 mg in the American market. The company has got the permission...
Aurobindo Pharma has received the green signal from the USFDA to market the generic version of Prilosec delayed-release capsule in the strengths of 10mg, 20mg, and 40 mg in the American market. The company has got the permission to manufacture and market Omeprazole delayed-release, used for short-term treatment of active duodenal ulcer in adults.
As confirmed by PTI,
The company's approved abbreviated new drug application (ANDA) is a generic version of AstraZeneca Pharmaceuticals' Prilosec capsules, confirmed the company in a media statement,
According to IMS, the product had an estimated market size of USD 422 million for the twelve months ended June 30.
In a separate statement, the company said it has received approval from the USFDA to market generic version of Hoffmann-La Roche's Boniva injection in the American market.
The company's Ibandronate Sodium injection is indicated for the treatment of osteoporosis in postmenopausal women.
Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country.She is a member of the Association of Healthcare Journalists. She can be contacted at email@example.com. Contact no. 011-43720751